Experimental trials with Gd(DO3A)--a nonionic magnetic resonance contrast agent.
Gd(DO3A), a member of a new family of nonionic MRI contrast agents, was evaluated in vivo in a rat model. In 10 animals, enhancement of an intracerebral glioma was studied following Gd(DO3A) injection. Correlation with tissue pathology was obtained in all cases. Comparative studies of renal enhancement were performed in 15 animals, utilizing disodium Gd(DTPA)2-, sodium-Gd(DOTA)-, and Gd(DO3A). With the glioma model, Gd(DO3A) administration provided enhancement of tissue with an altered blood brain barrier, thus permitting identification of the bulk of the neoplastic lesion. Comparative studies revealed that enhancement of normal renal medulla was equal or superior with Gd(DO3A).